RIGL Rigel Pharmaceuticals

$RIGL Dino’s talk was full of great content. His words not mine-we believe Vep has a well over a billion dollar market opportunity. He laid out how the salesforce is reaching the care providers. Was strong on guidance and said that it doesn’t consider Vep which they believe is a considerable opportunity. Added more! Volume is terrible today, but this will rocket if Vep is anything like they are projecting.

$RIGL great presentation by Dean, he is super bullish on the Vep launch. Nice to hear such extreme confidence, sounds like we can expect great things from Q3 earnings. No update on early sales numbers, but I’m okay with that - just means we’ll get a bigger blowout when they report earnings.

$RIGL shorts are stuck. FTD’s have went up in the past couple months and they simply won’t get out of that trade because look at this volume. There isn’t any way anyone is selling here when even the analysts say it’s undervalued. Let them keep shorting to manipulate this as much as they can but at the end of it all, they are screwed. Which is why you see a jump as soon as they drive it down a little. They are eager to get out of it but simply cannot. Squeeze is coming.

$RIGL Rigel confirmed today that the VEPPANU launch is on track. The drug became commercially available in August 2026, and patients started receiving it almost immediately. Rigel believes VEPPANU could eventually become its largest product, even bigger than TAVALISSE. The company sees a potential market opportunity of more than $1.X billion. Rigel estimates around 20,000 eligible patients in the relevant second- and third-line treatment setting. The company has built a dedicated commercial team to support the launch. Rigel has now achieved eight consecutive quarters of profitability. Its 2026 revenue guidance remains $285–295 million, excluding VEPPANU sales. R289 is another major upcoming catalyst, with preliminary data expected by the end of 2026. Overall, today’s update is bullish, although the first meaningful VEPPANU sales numbers could be the much bigger stock-price catalyst.

$RIGL RIGL’s borrow fee will likely only rise significantly once shares available to borrow become scarce and demand from short sellers remains high.

$RIGL Why haven't the rights to REZ been sold in Europe yet? Any thoughts? And when might the first sales of rights to Vepp take place?